LabVantage

LabVantage is a provider of integrated laboratory informatics solutions serving multiple industries including pharmaceuticals, biotechnology, biobanking, diagnostics, food & beverage, oil & gas, contract testing, cancer research, public health, consumer packaged goods, forensic laboratories, government, and medical laboratories. The company offers a comprehensive platform combining LIMS, ELN, LES, SDMS, and Mobile IoT capabilities.

Headquartered in Somerset, New Jersey, LabVantage has been recognised as a Frost Radar Leader for 3 consecutive years in LIMS. The company is privately held with Bregal Sagemount as an investor. LabVantage has received total funding of $208M, though specific funding rounds show conflicting reports ranging from $2M–$3M, which may represent specific investment tranches.

The company's flagship product, LabVantage LIMS, provides FDA 21 CFR Part 11, EU Annex 11, and GxP compliance capabilities. Additional platform components include BioTech360 for biotech-specific workflows and AILANI, an AI-powered search tool. The platform supports both cloud and on-premise deployments with enterprise integration capabilities.

LabVantage serves a global customer base across multiple regulated industries, with particular focus on laboratories requiring comprehensive compliance, audit trails, electronic signatures, and dynamic auditing capabilities. The company supports TGA, FDA, and EMA standards for global pharma operations.

LabVantage is a multi-industry laboratory informatics provider, not pharma-exclusive. The platform serves pharmaceuticals and biotechnology alongside numerous other industries including biobanking, diagnostics, food & beverage, oil & gas, contract testing, cancer research, public health, consumer packaged goods, forensic, government, and medical laboratories.

The platform provides FDA 21 CFR Part 11, EU Annex 11, and GxP (GMP/GLP) compliance capabilities supporting global pharma operations with TGA, FDA, and EMA standards. LabVantage serves pharmaceutical and biotech customers requiring comprehensive compliance, audit trails, electronic signatures, and dynamic auditing. Pharma customer names and total customer counts are undisclosed. The platform does not offer a pharma-specific product edition but supports pharma regulatory requirements within its multi-industry platform. BioTech360 module provides specialized workflows for biotechnology operations.

LabVantage has received $208M in total funding across multiple rounds. The company is privately held with Bregal Sagemount as an investor. Specific funding-round amounts show conflicting reports: some sources cite $2M–$3M, which may represent individual investment tranches rather than total funding.

Annual revenue estimates vary across sources: $92M per some sources, $164.2M per others. Revenue year and growth rate are undisclosed.

Employee count is disputed: 500+ per one range, 750+ per another. LabVantage has been operational for multiple years, with 3 consecutive years of recognition as a Frost Radar Leader in LIMS. M&A activity and acquisition history are undisclosed.

LabVantage offers an integrated laboratory informatics platform combining multiple product components. The flagship product is LabVantage LIMS (Laboratory Information Management System) which includes integrated Electronic Lab Notebook (ELN), Laboratory Execution System (LES), Scientific Data Management System (SDMS), and Mobile IoT capabilities. Additional modules include BioTech360 for biotech-specific workflows and AILANI, an AI-powered search tool for rapid data discovery.

The platform follows a comprehensive suite approach with modular components that can be deployed together or individually. Additional features include AI-powered search through AILANI, Mobile IoT for field data collection and remote laboratory access, and Dynamic Auditing that captures temporary memory changes before saving. The platform supports both cloud and on-premise deployment options. Additional capabilities include custom query capabilities for ad-hoc reporting, comprehensive audit trails capturing user ID, date/time, reason for change, original and new values, and enterprise integration capabilities for connecting with ERP systems and laboratory instruments.

Partnership information is undisclosed. The platform provides enterprise integration capabilities for connecting with ERP systems, laboratory instruments, and other enterprise applications. Undisclosed: technology partnerships with cloud providers, implementation partners, and industry affiliations.

LabVantage provides implementation services ranging from $5K–$50K, depending on organisation size, from small business to enterprise deployments. Customisation services are available at $5K–$20K for specific configuration needs. Training is provided at $200–$500 per user. Implementation timeline ranges from 6 months to over 1 year for complete deployment, depending on complexity.

LabVantage's support quality rating on G2 is 7.6/10. Users note that the platform requires significant implementation support due to complexity in configuration. Professional services appear focused on implementation, customisation, and training. Undisclosed: support availability (24/7, regional coverage), customer success programmes, user community events, and certification programmes.

LabVantage has been recognised as a Frost & Sullivan Radar Leader in LIMS for 3 consecutive years.

The company is backed by Bregal Sagemount as an investor and has received $208M in total funding. It has 500+ employees and operations spanning multiple industries globally. Undisclosed: certifications (ISO 9001, ISO 27001, SOC 2), leadership team details, thought leadership activities, and additional awards. The platform provides FDA 21 CFR Part 11, EU Annex 11, and GxP compliance capabilities.

LabVantage's G2 listing shows 19 reviews at 3.8/5. The company maintains a web presence at labvantage.com and has been a Frost Radar Leader in LIMS for 3 consecutive years. It has 500+ employees and global operations supporting TGA, FDA, and EMA standards.

Undisclosed: content resources, social media activity, press release frequency, free trial availability, and demo options. The multi-industry approach spans pharmaceuticals, biotechnology, diagnostics, food & beverage, oil & gas, and other sectors, beyond pharma-exclusive positioning.